AFRRI/NIAID partnership and validated animal models significantly derisk regulatory and commercial advancement of Company's lead candidatePositive momentum further positions Entolimod as a potential first and only treatment for GI-ARS, representing a multi-billion-dollar commercial opportunitySAN ANTONIO, June 25, 2026…
News provided by PR Newswire.
